Market Analysis and Insights: Global Nicotine Gums and Lozenges Market
Due to the COVID-19 pandemic, the global Nicotine Gums and Lozenges market size is estimated to be worth US$ 419.9 million in 2022 and is forecast to a readjusted size of US$ 601.3 million by 2028 with a CAGR of 6.2% during the review period. Fully considering the economic change by this health crisis, 2 mg/piece accounting for % of the Nicotine Gums and Lozenges global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR in the post-COVID-19 period. While Withdrawal Clinics segment is altered to an % CAGR throughout this forecast period.
China Nicotine Gums and Lozenges market size is valued at US$ million in 2021, while the US and Europe Nicotine Gums and Lozenges are US$ million and US$ million, severally. The proportion of the US is % in 2021, while China and Europe are % and % respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe Nicotine Gums and Lozenges landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period.
The global key manufacturers of Nicotine Gums and Lozenges include Novartis, Perrigo Company, Pharmacia, Fertin Pharma, Revolymer, Johnson & Johnson, Alchem International, Cambrex Corporation and GlaxoSmithKline, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
Global Nicotine Gums and Lozenges Scope and Segment
Nicotine Gums and Lozenges market is segmented by Type and by Application. Players, stakeholders, and other participants in the global Nicotine Gums and Lozenges market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
2 mg/piece
4 mg/piece
Other
Segment by Application
Withdrawal Clinics
Medical Practice
Individual Smokers
Others
By Company
Novartis
Perrigo Company
Pharmacia
Fertin Pharma
Revolymer
Johnson & Johnson
Alchem International
Cambrex Corporation
GlaxoSmithKline
Reynolds American
Dr. Reddy's Laboratories
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE